Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sung Yong Oh, Dong-A University Hospital
ClinicalTrials.gov Identifier:
NCT01213095
First received: September 30, 2010
Last updated: November 2, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: September 2015
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)